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The distribution of the apparent 
diffusion coefficient as an 
indicator of the response to 
chemotherapeutics in ovarian 
tumour xenografts
Monique C. Tourell1, Ali Shokoohmand1,2, Marietta Landgraf1, Nina P. Holzapfel1, 
Patrina S. P. Poh3, Daniela Loessner1,* & Konstantin I. Momot1,*
Diffusion-weighted magnetic resonance imaging (DW-MRI) was used to evaluate the effects of single-
agent and combination treatment regimens in a spheroid-based animal model of ovarian cancer. Ovarian 
tumour xenografts grown in non-obese diabetic/severe-combined-immunodeficiency (NOD/SCID) 
mice were treated with carboplatin or paclitaxel, or combination carboplatin/paclitaxel chemotherapy 
regimens. After 4 weeks of treatment, tumours were extracted and underwent DW-MRI, mechanical 
testing, immunohistochemical and gene expression analyses. The distribution of the apparent diffusion 
coefficient (ADC) exhibited an upward shift as a result of each treatment regimen. The 99-th percentile 
of the ADC distribution (“maximum ADC”) exhibited a strong correlation with the tumour size (r2 = 0.90) 
and with the inverse of the elastic modulus (r2 = 0.96). Single-agent paclitaxel (n = 5) and combination 
carboplatin/paclitaxel (n = 2) treatment regimens were more effective in inducing changes in regions 
of higher cell density than single-agent carboplatin (n = 3) or the no-treatment control (n = 5). The 
maximum ADC was a good indicator of treatment-induced cell death and changes in the extracellular 
matrix (ECM). Comparative analysis of the tumours’ ADC distribution, mechanical properties and ECM 
constituents provides insights into the molecular and cellular response of the ovarian tumour xenografts 
to chemotherapy. Increased sample sizes are recommended for future studies. We propose experimental 
approaches to evaluation of the timeline of the tumour’s response to treatment.
Diffusion-weighted magnetic resonance imaging (DW-MRI) is a well-established technique for quantitative 
evaluation of high-cellularity tumours in both clinical and research settings. The apparent diffusion coefficient 
(ADC) measured from DW-MRI is sensitive to the tumour microenvironment. As a result, the ADC is a potential 
non-invasive biomarker for the initial identification of tumour masses, as well as prediction and monitoring of 
response to therapy1–6.
ADC is negatively correlated with the tumour cellularity, with high cell density and extracellular tortuosity 
resulting in increased restriction on the diffusion of water molecules7–9. Conversely, apoptotic or necrotic areas of 
tumours are associated with elevated ADC values as a result of decreased cell density10–12, while high-cellularity 
tumours may exhibit significantly decreased ADC values13–16.
ADC values in tumours are also known to increase in response to anti-cancer therapy17–19. A lower number 
of proliferating cells and a higher number apoptotic cells are indicators of therapy success. The decrease in cell 
density, as well as structural changes that precede or accompany cell death (e.g. cellular shrinkage during apop-
tosis or membrane rupture during necrosis), lead to reduced restriction of water diffusion in both intra- and 
extracellular spaces. The subsequent increase in ADC values has been observed in tumour xenografts20–26 and 
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patient-derived samples27–31 for a wide variety of tumour entities and therapeutic regimens. Some of these studies 
have included treatment using platinum-26,30,31 and taxane-based20,29–31 chemotherapeutics. Besides mean ADC 
values, the changes of ADC distributions in response to therapy have also been investigated and found to be a 
more comprehensive indicator of this response than the mean ADC alone30.
Combination platinum/taxane-based chemotherapy is the standard first-line therapy in the clinic for the 
treatment of patients diagnosed with ovarian cancer32. The individual effect of single-agent platinum or taxane 
and combination platinum/taxane treatment on the ADC in ovarian tumour xenografts has not yet been deter-
mined. However, their general effect has been studied implicitly in clinical research. Kyriazi et al.30 and Sala et al.31 
reported a 16% and 28% increase in the mean ADC of water in platinum- or taxane-responsive ovarian tumours, 
respectively.
In the present study, we examined the effect of different chemotherapy regimens, single-agent platinum and 
taxane and combination platinum/taxane, on the ADC distributions in ovarian tumour xenografts derived from 
human serous ovarian cancer cells, using diffusion-weighted magnetic resonance microimaging. Microimaging 
enables enhanced spatial resolution compared to clinical MRI, and can provide information on the local micro-
scopic environment and macroscopic organisation of the sample. We observed changes in the ADC distribu-
tions of the tumours as a result of each of the treatment regimens. We discuss these observations in terms of the 
relationship between tumour response to chemotherapy and the production of extracellular matrix (ECM) and 
propose future experiments that would provide insights into the detailed time line of this response.
Methods
Animal Study. The animal experiment was performed in compliance with the Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes and approved by the University Animal Research Ethics 
Committees (Queensland University of Technology approval 0900000578; University of Queensland approval 
QUT/287/11). Surgery using 6-week old female NOD/SCID mice was performed as described previously33. 
Polyethylene glycol-based hydrogels were used as an ovarian cancer OV-MZ-6 cell spheroid delivery vehicle. 
These were implanted intra-peritoneally between the ovarian bursa and nearby fat tissue, adjacent to both ovaries. 
Tumour growth was assessed weekly via bioluminescence as reported earlier33. To examine therapeutic effects of 
platinum/taxane treatment on tumour growth, treatment started 4 weeks post-implantation according to our pre-
vious study33. The treatment regimen consisted of either carboplatin (Sigma-Aldrich, Castle Hill, NSW, Australia; 
15 mg/kg/dose), or paclitaxel (Sigma-Aldrich; 10 mg/kg/dose), or a combination of both chemotherapeutics, 
given twice per week each in an alternating manner for all treatment groups, via intra-peritoneal injections for 4 
weeks (5 mice per group). Saline or DMSO served as control treatment. Eight weeks post-implantation, animals 
were sacrificed, and tumour tissues were removed and subjected to DW-MRI, mechanical testing, immunohisto-
chemical and gene expression analyses.
DW-MRI. Fresh, non-fixed tumour tissue samples were placed on top of a custom-made Teflon plug posi-
tioned at the bottom of a 10 mm NMR tube (Wilmad) in phosphate-buffered saline (PBS). Samples thus prepared 
and refrigerated can be stored for at least a week, as shown in our previous study35. A second Teflon plug was 
positioned above the sample, allowing ~5 mm of PBS between the samples and top plug for calibration of the 
diffusion data. The total distance between the two Teflon plugs ranged from 10 to 15 mm. MRI measurements 
were performed at room temperature on a Bruker Avance NMR spectrometer with a 7.0 T vertical bore supercon-
ducting magnet equipped with a Micro2.5 micro-imaging probe and a triple-axis gradient set (maximum gradi-
ent amplitude 1.2 T/m)34. A 10 mm birdcage RF coil was used. For all measurements, the imaging plane passed 
through the centre point of the NMR tube and was vertical (aligned with the long axis of the NMR tube and B0). 
The Read direction was in the direction of the B0 field.
A Fluid-Attenuated Inversion Recovery (FLAIR) spin-echo imaging sequence was initially used to locate the 
position of the samples in the NMR tube and to determine the appropriate imaging plane for the diffusion meas-
urements. FLAIR parameters were similar to those reported in our previous study35. The duration of the inversion 
recovery interval was empirically chosen as 1.4 s in order to minimise the PBS signal. From these images, the azi-
muthal orientation of the vertical imaging slice for the diffusion imaging was chosen such as to contain the largest 
cross-section of the tumour tissue sample.
Diffusion imaging was performed using a spin-echo diffusion-weighted pulse sequence with TR = 3 s, 
TE = 14 ms and 3-lobe sinc RF pulses (1 ms duration for the excitation 90° pulses and 0.749 ms for the refocusing 
180° pulses). Slice thickness was selected to accommodate the sample size. For the control, single-agent carbo-
platin and paclitaxel treatment groups, the slice thickness was set to 0.4 mm; for the combination carboplatin/
paclitaxel treatment group, to 0.3 mm. In-plane imaging parameters were: FOV = 19.8 mm (Read) × 14.9 mm 
(Phase), NR × NP = 170 × 128 (zero-filled to 256 × 128). The diffusion gradient direction was Read. The 
diffusion-weighing gradients had the duration δ = 2 ms, with the gradient separation (diffusion interval) 
Δ = 7 ms. The largest gradient amplitude used was 63% of the rated maximum amplitude (g ≤ 0.76 T/m). For 
each group, 8 diffusion-weighted images were acquired with b values equally spaced from 0 to 1400 s mm−2. The 
linearity of the Stejskal−Tanner plots (checked for a representative selection of voxels from both the tumour and 
the PBS regions) was used to ensure the absence of thermal convection or mechanical vibration effects.
Mechanical Testing. Unconfined mechanical compression testing of fresh, non-fixed tumour tissue samples 
was conducted using an Instron 5848 micro-tester fitted with a 5 N load cell at 37 °C, with PBS as the immersion 
medium as described previously35. Samples were subjected to 30% compression relative to the uncompressed 
height at a rate of 5 mm per minute, and the Young’s modulus was determined at 25% strain using the stress versus 
strain data set.
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Immunohistochemistry. Haematoxylin/Eosin (H&E) staining and immunohistochemical analysis were 
performed on serial paraformaldehyde-fixed paraffin-embedded tumour tissue sections (5 μm), from the same 
tumour tissue samples as used for DW-MRI. H&E staining was conducted to visualise tissue morphology using 
a standard procedure as reported previously36. For immunohistological analysis, samples were deparaffinised in 
xylene and rehydrated in dilutions of ethanol and water. Antigen retrieval was performed using a high-pH buffer 
(pH 9) at 95 °C for 10 min. Then, samples were treated with 3% H2O2 and blocked with 2% bovine serum albumin 
(BSA)/PBS. The human-specific antibodies against the nuclear mitotic apparatus protein 1 (NuMA; Epitomics, 
Burlingame, CA, USA) and Ki67 (#MIB-1; Dako, Sydney, NSW, Australia) were applied 1:100 and 1:75, respec-
tively, in 2% BSA/PBS as reported previously36. After washing, sections were incubated with EnVision+Dual Link 
System-horseradish peroxidase (HRP; Dako), followed by 3,3′-diaminobenzidine chromogen (Dako) and Mayer’s 
haematoxylin (Sigma-Aldrich) staining. Sections were imaged using an automatic Leica slide scanner with a 40x 
magnification and archived on a digital image hub. Quantification of Ki67-stained sections was performed using 
ImageJ (NIH, Bethesda, MD, USA), and the percentage of the positively stained tissue area was calculated.
Calculation of ADC. A custom in-house Mathematica code (Wolfram Research, Champaign, IL, USA) was 
used for the analysis of all MR images. A region of interest (ROI) containing voxels of only PBS was identified in 
the diffusion-weighted images and used to calibrate the effective b-values as described previously35. The calibrated 
b-values were then used to construct the apparent diffusivity maps for each treatment group by constructing a lin-
earised Stejskal−Tanner diffusion plot and performing a linear least-squares fit of the signal decay in every ROI 
voxel. The tumour ROI for ADC analysis was determined by inspection of the ADC maps thus constructed, with 
reference to FLAIR, diffusion-weighted MR and immunohistochemical images. Excluded from the ROIs were 
regions of murine muscle and fat tissues and tumour regions that had been infiltrated by surrounding murine 
tissue. Additionally, tumour regions near sutures (easily identified in the reference diffusion images acquired with 
b = 0 s mm−2) were avoided. Histograms of the diffusivities for each treatment group were constructed from the 
tumour ROIs. The distributions were compared using the pairwise Mann-Whitney test.
Measurements of Tumour Area. The histological area of tumour tissue sections using only the 
NuMA-positive tumour regions was calculated using ImageJ. The cross-sectional area of the tumours visible in 
the MRI analysis was calculated by drawing a ROI around the solid tumour tissues. This region was typically not 
identical to the one used to construct the ADC map. The uncertainty in these areas was calculated by adding or 
subtracting a layer, one pixel wide, to the perimeter of the regions. The longest axis of each separate, solid mass 
visible in the MR image was also measured. The uncertainty in each measured length was the length of two pixels.
Gene Expression Analysis. Tumour tissues were dispersed with a tissue homogeniser, and RNA 
extracted using Trizol® reagent (Life Technologies, Mulgrave, VIC, Australia) following the manufac-
turer’s instructions. RNA quality was determined with a Nanodrop® ND-1000 spectrophotometer (Life 
Technologies), and samples with A260nm/230nm = 2.05–2.15 were synthesised into cDNA using a Superscript™ 
III first-strand synthesis supermix (Life Technologies) following the manufacturer’s instructions. Quantitative 
RT-PCR was performed using SYBR® green chemistry using an ABI Prism® 7500 sequence detection sys-
tem (Life Technologies) as reported previously33. Gene-specific primer sets are listed 5′-3′, forward and 
reverse respectively: FN1 GTGTGACCCTCATGAGGCAAC and CTGGCCTCCAAAGCATGTG, VTN 
TGCTGGCATGGGTTGCT and GTTCATGGACAGTGGCATTGTT, COL1A1 GTGCTCCTGGTATTGCTGGT 
a n d  AC C AG G T T C AC C G C T G T TAC ,  H I F 1 A  G G G T T G A A AC T C A AG C A AC T G T C  a n d 
G T G C T G A ATA ATA C C A C T C A C A A C G ,  1 8  S  G AT C C AT T G G A G G G C A A G T C T  a n d 
CCAAGATCCAACTACGAGCTTTTT. The cycle threshold (Ct) of each gene of interest was determined and 
normalised to 18 S expression levels and compared to the control (ΔΔCt). Relative gene expression between 
treatment groups was calculated using the 2−ΔΔCt method.
Results
Immunohistochemistry. H&E staining of the complete set of the xenograft samples from all the tumour 
tissues analysed by DW-MRI has revealed the morphological heterogeneity of the tissues. At the tumour mar-
gins, murine muscle and/or fat tissues were apparent (Fig. 1, top). NuMA staining enabled specific identification 
of the tumour tissue areas, with large tumours in the control group, and small or minimal tumour regions in 
all treatment groups (Fig. 1, middle). Ki67 staining indicated that cell proliferation was reduced in treatment 
regimens containing paclitaxel compared to the control and single-agent carboplatin treatment groups (Fig. 1, 
bottom). Quantitative image analysis of the percentage of the positively stained tissue area revealed a significant 
reduction of proliferating cells upon single-agent paclitaxel (0.31 ± 0.05; P < 0.001) and combination carboplatin/
paclitaxel (0.23 ± 0.07; P < 0.001) compared to the control (3.03 ± 0.63), while the single-agent carboplatin group 
(3.45 ± 0.64) displayed a similar amount of Ki67 positive cells as seen in the control group.
DW-MRI. FLAIR images for each treatment group (Fig. 2a–d) indicated that the tumour and the murine mus-
cle tissues were not clearly distinguishable on the basis of relaxation-weighted images alone. Murine fat tissue, 
predominantly observed in the control and carboplatin treatment groups (Fig. 1), had a relatively short T1 com-
pared to PBS and the muscle tissue, and appeared hyper-intense in the FLAIR images (Fig. 2a,b). Solid tumour 
regions were identified from the ADC maps constructed for each of the different treatment groups (Fig. 2e–h), 
with reference to the H&E and histological images and the calculated ADCs. Tumour regions appeared as darker 
grey areas in the ADC maps, while lighter grey areas in the ADC maps, often surrounding the tumour tissue, were 
identified as murine muscle tissues.
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ADC. The ROIs used to calculate the ADC distributions for each of the treatment groups are indicated by the 
red lines in Fig. 2e–h. The ADC distributions of the single-agent carboplatin, paclitaxel and combination carbo-
platin/paclitaxel treatment groups are shown next to the control group in Fig. 3a–c. A quantitative summary of 
each ADC distribution is given in Table 1. The ADC distribution of each treatment group was found to be signif-
icantly different (α = 10−4) from the control group on the basis of the pairwise Mann-Whitney test (see Table 2). 
For all treatment groups, the ADC distributions exhibited a shift towards higher ADC values compared to that 
of the control group (Fig. 3a–d, Table 1). The change in ADC values from the control group was non-uniform 
and dependent on the treatment regimen. The mean ADC value of the single-agent carboplatin group was 
significantly different from the single-agent paclitaxel and combination carboplatin/paclitaxel mean ADC 
values (Table 2). However, there was no statistically significant difference between the ADC distributions of the 
single-agent paclitaxel and the combination carboplatin/paclitaxel treatment (Table 2).
Tumour Area. The total tumour area was calculated from both the histological images and ADC maps 
(Table 3). Tumours from the control group exhibited the highest cross-sectional area and the largest sum of the 
tumour axes. The combination carboplatin/paclitaxel treatment group displayed the smallest tumour areas. There 
was a moderate correlation (r2 = 0.74–0.90) between the cross-sectional size of the tumours, measured from the 
histological images, and the mean and maximum ADC values (Fig. 4a,c).
Mechanical Testing. The elastic moduli of the tumour samples from all treatment groups were measured 
by unconfined compression testing and averaged over the given group. The results are shown in Table 4. For all 
Figure 1. H&E staining and immunohistochemical analysis of the different treatment groups. Tissue 
morphology is indicated by H&E staining as an overview and close-up of the tissue samples (scale bars, 1 mm; 
T – tumour tissue, M – muscle tissue, F – fat tissue, S – suture). Paclitaxel-containing treatments resulted in 
smaller tumour regions compared to single-agent carboplatin and the control (no treatment). Representative 
images of nuclear NuMA and Ki67 stainings are indicated in brown for all groups, with the control and single-
agent carboplatin groups showing a higher number of proliferating cells (scale bars, 20 μm).
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treatment groups, the elastic moduli were higher than the elastic modulus for the control group. The strong-
est increase was observed for the combination carboplatin/paclitaxel treatment group. A strong correlation 
(r2 = 0.85–0.96) between the inverse of the elastic modulus and the mean as well as the maximum ADC was 
observed across the treatment groups (Fig. 4b,d).
Gene Expression. The changes in the gene expression of ECM constituents for each of the treatment groups 
relative to the control group were evaluated (see Table 5). As the results were obtained from one tumour sample 
per group, we regard these changes only as a qualitative indication of an increase or decrease in gene expression. 
The combination carboplatin/paclitaxel treatment group displayed a consistent increase in the expression of all 
the ECM genes investigated, with an especially substantial increase in the expression of fibronectin (FN1).
Discussion
The use of clinical imaging to monitor tumour response to therapy continues to rely largely on changes in 
uni-dimensional measures of the tumour size, evaluated according to accepted standards, such as Response 
Evaluation Criteria In Solid Tumours (RECIST)37,38. However, measureable changes to tumour size occur late in 
therapy and cannot reflect treatment-induced physiological changes. As a result, there is a growing need for the 
development of imaging biomarkers that detect earlier treatment-induced changes at both macromolecular and 
microstructural levels. The ADC is one potential imaging biomarker that can be implemented in both clinical 
Figure 2. FLAIR images (top row) and ADC maps (bottom row) for the different treatment groups: (a) and 
(e) control (no treatment); (b) and (f) carboplatin; (c) and (g) paclitaxel; (d) and (h) combination carboplatin/
paclitaxel. The red lines in the ADC maps indicate the ROIs used for the histogram analysis.
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Figure 3. Comparison of the ADC distributions in the treatment and the control groups. The blue dotted 
line corresponds to the control (no treatment) group and is displayed together with each of the treatment 
groups: (a) carboplatin (green line); (b) paclitaxel (orange line); (c) combination carboplatin/paclitaxel (red 
line). The cumulative probability plots of all four ADC distributions is shown in (d). For clarity, only the splines 
of the distributions are shown.
Group Mean ± std. dev. (×10−3 mm2 s−1) Min. ADC (×10−3 mm2 s−1) Max. ADC (×10−3 mm2 s−1)
Control 0.53 ± 0.06 0.39 0.67
Carboplatin 0.56 ± 0.07 0.38 0.71
Paclitaxel 0.58 ± 0.06 0.46 0.71
Carboplatin/Paclitaxel 0.58 ± 0.06 0.47 0.77
Table 1.  ADC distributions for the different treatment groups corresponding to the ROIs shown in Fig. 2. 
The mean ADC value was equal to the median ADC value in the ADC distributions of all groups. The minimum 
and maximum ADC values were calculated as the 1st and 99th percentiles, respectively.
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Group Control Carboplatin Paclitaxel
Carboplatin/
Paclitaxel
Control — 3.4 × 10−14 5.5 × 10−45 3.5 × 10−20
Carboplatin 3.4 × 10−14 — 2.0 × 10−11 4.7 × 10−5
Paclitaxel 5.5 × 10−45 2.0 × 10−11 — 0.3
Carboplatin/Paclitaxel 3.5 × 10−20 4.7 × 10−5 0.3 —
Table 2.  Pairwise Mann-Whitney testing of the different groups. Each treatment group was found to be 
significantly different from the control group (no treatment). Bolded values indicate no statistically significant 
difference between the two distributions at α = 10−4.
Group
Histological area 
(mm2)
MRI area 
(mm2)
Sum of the 
longest axes MRI 
(mm)
Control 63 ± 14 52 ± 7 19.9 ± 0.8
Carboplatin 21 ± 9 29 ± 6 15.2 ± 0.8
Paclitaxel 32 ± 11 18 ± 3 10.2 ± 0.6
Carboplatin/Paclitaxel 11 ± 6 6 ± 1 3.7 ± 0.3
Table 3.  Total tumour area calculated in both the histological and MRI analyses.
Figure 4. The mean ADC, < ADC >, (a) and (b), and the maximum ADC, (c) and (d), correlated with 
tumour cross-sectional size and elastic modulus, respectively. The black, dashed line in each plot is the least 
squares fit of the data, r2 values are displayed in the plots. For all plots, the blue square is the control group; the 
green diamond, single-agent carboplatin group; yellow triangle, single-agent paclitaxel group; and red circle, 
carboplatin/paclitaxel treated tumours. In panel (d) the single-agent carboplatin and single-agent paclitaxel 
treatment groups are overlapped.
Group
Number of 
samples
Mean ± std. dev. 
(kPa)
Control 5 0.9 ± 0.4
Carboplatin 3 2.3 ± 1.4
Paclitaxel 5 2.4 ± 1.0
Carboplatin/Paclitaxel 2 6.1 ± 0.7
Table 4.  The Young’s modulus of the different treatment groups averaged over the number of tumour 
tissue samples tested.
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and research settings. Diffusion of water in biological tissues is affected by a range of intra- and extracellular 
characteristics, including cell density, morphology, membrane permeability and ECM composition. At high cell 
densities, these effects are amplified7,39, and the measured ADC is highly susceptible to changes in the tumour 
microenvironment. Thus, the ADC is well-suited for quantitative evaluation of tumour responses to therapy. The 
development of functional imaging biomarkers, such as the ADC, is particularly important for ovarian cancer, 
where the application of RECIST can be difficult40. Despite this, the literature on changes to ADC values and 
comparative analysis of the ADC distributions in ovarian lesions as a result of treatment are limited.
ADC in Ovarian Cancer. The potential of the ADC as an imaging biomarker for the detection and stag-
ing of ovarian cancers has been studied more widely than the use of the ADC as a tool for monitoring tumour 
response to therapy13,14,41–47. However, there have been varying findings as to the usefulness of the ADC in regard 
to the former due to the broad overlap between the ADC distributions of benign and malignant lesions. This 
overlap is a result partly of the variation of the anatomy and the progression of the tumours, and partly a result 
of the existence of different tumour subtypes13,43,47. The OV-MZ-6 cells used in the present study to generate the 
tumour xenografts were established from a patient diagnosed with advanced serous cystadenocarcinoma (FIGO 
IV) of the ovary48. The reported mean ADC values measured in serous adenocarcinomas from clinical studies 
are displayed in Table 6. In the present study, the mean ADC was (0.53 ± 0.06) × 10−3 mm2 s−1 for the control 
group (no treatment); this is substantially less than the values reported previously in patient-derived tissues. This 
is not surprising, given the advanced stage (FIGO IV) of the tumour xenografts in the present study combined 
with research-imaging conditions. Lower mean ADC values have been linked to higher FIGO stages in serous 
adenocarcinomas41. The other factor responsible for the differences between the present and previously reported 
mean ADC values is that the diffusion measurements in the present study were performed at 25 °C, which 
corresponds to the bulk-water diffusion coefficient ~30% lower than at the standard physiological 
temperature (37 °C)49,50.
Sample Size. The intraperitoneal ovarian cancer animal model used and the number of animals per group 
are consistent with the protocol established by our group previously33. The animal study was conducted using 
5 NOD/SCID mice per group over 8 weeks, with treatment (control, carboplatin, paclitaxel, carboplatin/paclitaxel) 
starting in week 4 post implantation of spheroid-loaded hydrogels. A similar sample size has been demonstrated 
to provide statistically reliable results in our previous studies33.
The inter-group differences in the response to treatment explain the different numbers and sizes of the tumour 
samples available for the DW-MRI measurements and mechanical testing from each treatment group. From the 
carboplatin and the control groups, which were less responsive to treatment, three and five samples, respectively, 
were recovered for subsequent analysis; these samples exhibited a relatively large size (see Table 3). From the more 
responsive paclitaxel-treated groups, two and five samples, respectively, were available; the sizes of the samples 
were relatively small. Due to the surrounding murine tissue, only clearly identifiable tumour areas were included 
in the DW-MRI analysis, as indicated in the FLAIR images (see Fig. 2). Despite the differences in the number 
and the size of the samples obtained from different groups, the tumour samples in each group originated from 
the same number of animals. As a result, the MRI measurements essentially compared the combined tumour 
burden of the five animals present in each group, and therefore the intergroup comparison was not biased by the 
differences in tumour sample sizes.
ADC Changes in Response to Treatment. The mean ADC values exhibited an increase in the treated 
tumours compared to control (no treatment) tumours. The combined mean ADC of the treated tumours was on 
average 7.5% larger than that of the control. Similar increases in the mean ADC have been observed in clinical 
studies of patients with ovarian cancer treated with different combination platinum/taxane regimens as displayed 
in Table 6 30,31,51. An increase in the ADC values in treated tumours is consistent with an increase in extracellu-
lar space following cell death through various mechanisms52. In ovarian cancer, carboplatin and paclitaxel are 
known to induce apoptosis53, which has been directly linked to increases in the ADC23,52,54. While the ADC values 
increased in all treatment groups compared to the control, this change was not equal across the distribution of the 
ADC. Kyriazi et al.30 have also demonstrated that changes to ADC distributions in ovarian cancers in response to 
carboplatin- or paclitaxel-based treatments are heterogeneous. The spatial heterogeneity of tumour responses to 
treatment is an ongoing problem in the development of the ADC as an imaging biomarker for tumour responses 
to therapy55–57. The variation in tumour response may be due to spatial heterogeneity in the pre-treatment tumour 
tissues. In addition, changes to the ADC in response to treatment are also heterogeneous. In the present study, 
Group FN1 VTN COL1A1 HIF1A
Control 1.00 ± 0.06 1.00 ± 0.11 1.00 ± 0.02 1.00 ± 0.04
Carboplatin 2.68 ± 0.29 2.18 ± 0.06 0.89 ± 0.04 1.87 ± 0.07
Paclitaxel 1.35 ± 0.03 0.72 ± 0.17 1.02 ± 0.02 0.72 ± 0.02
Carboplatin/Paclitaxel 20.04 ± 0.38 2.49 ± 0.28 3.01 ± 0.05 3.47 ± 0.06
Table 5.  Relative gene expression levels of different ECM proteins normalised to the control (no treatment) 
group (mean ± standard deviation).
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the variation of tumour response to treatment was observed separately in all the treatment groups tested, and was 
dependent on the treatment regimen.
Changes in Tumours Treated with Single-Agent Carboplatin or Paclitaxel. The results of the 
Mann-Whitney test demonstrate that the ADC distributions of the single-agent carboplatin and paclitaxel treat-
ments group were significantly different (Table 2). The mean ADC in the tumours treated with single-agent car-
boplatin or paclitaxel was 6% and 9% larger, respectively, than in the control. The difference in the change in the 
minimum ADC from the control group was more pronounced for the two single-agent treatment groups. The 
minimum ADC value (Table 1; defined as the first percentile of the ADC distribution) of the single-agent carbo-
platin treated group was within 2.5% of the minimum ADC value in the control group. However, the minimum 
ADC value for the single-agent paclitaxel treatment regimen was ~20% larger than the control. This suggests that 
the single-agent paclitaxel was more effective than single-agent carboplatin in inducing cell death in regions of 
higher cell density in the tumour xenografts, and resulted in the lower number of proliferating cells. Conversely, 
the maximum ADC value (Table 1; defined as the 99th percentile of the ADC distributions) was the same for both 
single-agent treatment regimens.
Changes in Tumours Treated with Combination Carboplatin/Paclitaxel. The tumours treated with 
combination carboplatin/paclitaxel were smaller in size, revealed the lowest number of proliferating cells and 
exhibited substantial increases in ECM constituents compared to the single-agent treated tumours. These obser-
vations indicate that the combination regimen was the most successful of the chemotherapy regimens investi-
gated. Changes in ECM constituents have been linked to chemo-resistance in ovarian tumours58, and increased 
fibronectin expression has been associated with cisplatin chemo-resistance in other cancer types59. Thus, increases 
in ECM constituents during treatment can be considered the tumour’s survival response to treatment and an indi-
cator of success or failure of chemotherapy.
There was no statistically significant difference between the mean ADC of the tumours treated with 
single-agent paclitaxel and the combination carboplatin/paclitaxel. Additionally, the minimum ADC values of 
both the single-agent paclitaxel and combination carboplatin/paclitaxel treatment groups were the same. This 
suggests that the difference between the lower portions of the ADC distribution curves (which correspond to 
the regions of tumours with relatively high cellularity) between the control and the combination carboplatin/
paclitaxel treatment groups can be attributed to paclitaxel.
In addition to changes in cell density, the ADC is sensitive to morphological and compositional changes 
in the ECM of tumour tissues. The increase in ECM constituents introduces additional obstructions and 
hydrogen-bonding sites to the tumour microenvironment, reducing the ADC. It is often observed, usually with 
reference to fibrosis, that later stages of chemotherapy may induce changes in the ECM of tumours that affect 
the ADC3,18,57. The sensitivity of the ADC to changes in the ECM suggests that interpretation of changes in the 
measured ADC in terms of treatment response at later time periods should include changes to ECM composition 
in addition to cell density.
It is not clear whether the magnitude of the increase in ECM proteins in the present study is sufficient to 
directly impact the measured ADC in the tumours treated with the combination carboplatin/paclitaxel. To inves-
tigate this further, we propose that imaging at multiple, earlier time points should be conducted in future studies. 
This would not only allow the changes to the ADC to be monitored throughout different stages of ECM pro-
duction, but also provide insight into the time dependence of ECM production in the tumour xenografts as a 
Study Ovarian tumour subtype (FIGO or number of patients or lesions) Mean ± std. dev. ( × 10−3 mm2 s−1)
Fujii et al.13 serous adenocarcinoma (n = 19) 1.32 ± 0.31
Zhang P et al.43 serous adenocarcinoma (n = 35) 0.97 ± 0.20
Zhang H et al.14 serous adenocarcinoma (n = 12) 1.12 ± 0.42
Oh et al.41
serous adenocarcinoma (FIGO I) 1.17 ± 0.36
serous adenocarcinoma (FIGO II-IV) 0.86 ± 0.15
Kyriazi et al.51
serous adenocarcinoma (FIGO III/IV), pre-treatment 0.90 ± 0.12
serous adenocarcinoma (FIGO III/IV), post-treatment (first cycle) 0.99 ± 0.13
serous adenocarcinoma (FIGO III/IV), post-treatment (second cycle) 1.05 ± 0.14
Kyriazi et al.30
serous papillary adenocarcinoma (n = 32), pre-treatment 1.08 ± 0.18
serous papillary adenocarcinoma (n = 32), post-treatment (first cycle) 1.22 ± 0.22
serous papillary adenocarcinoma (n = 26), post-treatment (third cycle) 1.30 ± 0.24
Sala et al.31
serous adenocarcinoma (n = 9), pre-treatment 1.02 ± 0.19
serous adenocarcinoma (n = 9), post-treatment (third cycle) 1.30 ± 0.29
The present study 
(measured in 
vitro at 25 oC)
serous adenocarcinoma xenografts (FIGO IV), no treatment 0.53 ± 0.06
serous adenocarcinoma xenografts (FIGO IV), post-treatment 0.58 ± 0.06
Table 6. Mean ADC values in serous ovarian carcinoma determined in patient-derived tissues and in the 
present study. If available, mean ADC values pre- and post-treatment are listed from patients responding to 
chemotherapy. All the measurements from the literature were made at the physiological temperature in vivo 
(~37 oC); the measurements in the present study were made in vitro at 25 oC.
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survival or apoptosis response to chemotherapy. This would enable the relationship between the measured ADC 
distribution and the molecular and cellular response of the tumours to therapy to be understood in greater detail.
The minimum and the mean ADC values exhibited no significant differences between combination carbopla-
tin/paclitaxel and single-agent paclitaxel treatment groups. Despite this, the maximum ADC for the combination 
carboplatin/paclitaxel treatment was ~8% larger than in the single-agent paclitaxel treatment group. Higher ADC 
values correspond to regions of lower cell and ECM density, making the ADC in these regions less susceptible 
to changes in ECM composition. Therefore, at later stages in chemotherapy, during ECM compositional or mor-
phological changes, the maximum ADC value may provide a better indication of treatment efficacy in terms of 
cell death alone.
Distribution of the ADC across the Tumour ROIs. Table 1 shows that, in any given treatment group, the 
ADC of the tumour tissue exhibits significant variations across the tumour region-of-interest. A useful indicator 
of the magnitude of these variations is the ratio of the 99th percentile (“the maximum ADC”) to the 1st percentile 
(“the minimum ADC”) of the ADC distribution; this ratio ranges between 1.54 for the paclitaxel-only group 
and 1.87 for the carboplatin-only group. The ADC distribution parameters shown in Table 1 also mean that the 
maximum ADC can be up to 32% larger than the corresponding mean ADC, while the minimum ADC can be as 
much as 33% lower than the mean ADC. ADC variations of this magnitude are not unusual: comparable or even 
larger ADC variations are routinely observed in other studies, including in vivo30. This can be attributed to at least 
two principal factors. First, the measurement of the ADC is subject to noise, which means that even in a hypo-
thetical perfectly uniform tissue the distribution of the ADC values measured in different voxels would exhibit a 
non-zero variance. The second factor is the heterogeneity of the tumour tissue, i.e., the inevitable variations in the 
cell density, vascularity, the composition and the density of the ECM and other morphological parameters across 
the ROI. As discussed above, these morphological factors affect the value of ADC, and their variation across the 
tumour ROI leads to additional variance of the ADC distribution. Separation of the ADC variance attributable 
to noise and to tissue heterogeneity would require a careful and technically demanding experimental design: for 
example, an accurate measurement of the true instrumental noise would likely require the use of highly uniform, 
carefully designed phantoms in order to exclude the effects of tissue heterogeneity. We have not attempted such 
separation in the present study; nor are we aware of attempts in other studies to separate the different contribu-
tions to ADC variance in tumours. Nevertheless, a number of observations suggest that ADC variations due to 
tumour heterogeneity are an important indicator of the status of the tumour and its response to treatment. In the 
present study, we have observed a stronger correlation between the maximum ADC values and the stiffness of 
the tumour than between the mean ADC and tumour stiffness (see the discussion below). Other authors have 
observed treatment-induced changes in the shape of the ADC distribution that differ between responders and 
non-responders30. The same authors have found that, based on the area under receiver operating characteristic 
curve (AUC) test, the relative change of the 25th ADC percentile was a better predictor of the response to treat-
ment than either the median ADC or the shape-based characteristics of the ADC distribution such as skewness 
and kurtosis. Recent experimental studies of breast tumours in vitro combined with diffusion modelling60 have 
found that MRI diffusion measurements of tumours are significantly influenced by the effects of restricted diffu-
sion and diffusion anisotropy. Both of these factors can result, independently of noise or tissue heterogeneity, in 
the presence of a distribution of ADCs as well as other diffusion-related characteristics; furthermore, the nature 
of the distribution can be strongly dependent on the nature of the model used to interpret the diffusion data. All 
these findings suggest that a hypothetical structureless, morphologically uniform tumour is not a good model to 
use in the interpretation of ADC measurements, and the entire ADC distribution (or, more generally, the distri-
bution of restricted-diffusion parameters) should be used when evaluating the response of the tumour to drug 
treatment on the basis of diffusion measurements.
ADC and Tumour Area. The idea that high-ADC regions are particularly indicative of treatment-induced 
cell death is reinforced by the correlation between the maximum ADC and tumour size. Of the different area 
measures reported in Table 3, the histological area, identified by NuMA-positive staining, is the most represent-
ative of the total tumour region. The maximum ADC showed a closer correlation with the cross-sectional area of 
the tumour samples, measured by histology, than the mean ADC values.
ADC and Elastic Modulus. There was a strong negative correlation (r2 = 0.96; Fig. 4d) between the maxi-
mum ADC values and the inverse of the elastic modulus. This is an apparently counterintuitive behaviour, which 
suggests that the treatment-induced reduction in tumour tissue (increasing ADC) was accompanied by an 
increase in the mechanical stiffness (decreasing 1/Young’s modulus). Previous studies have reported a decrease 
in shear stiffness as a result of anti-cancer treatment61,62; and increased stiffness in tumour tissue compared 
to normal tissue has been seen in various tumour types63–65. Nevertheless, treatment-induced increase in the 
mechanical stiffness of the tumour tissue has been observed in past tumour xenograft studies36. The strong corre-
lation between the maximum ADC values and the Young’s modulus of the xenografts (Fig. 4d) suggests that this 
increase has a biophysical basis in the tumour microenvironment and the response of this microenvironment to 
drug treatment. Investigation of changes in tumour stiffness in response to treatment is still a relatively new field 
of research, and a number of factors not yet understood could play a role. Stiffness in biological tissues is depend-
ent on both morphological and compositional characteristics of the ECM, as well as cell stiffness. Increased stiff-
ness in tumour tissue can be a result of an upregulation of the production of fibrous proteins, and the consequent 
formation of ECM structures that are larger, more rigid and more disordered than those in normal tissues66,67. 
The combination carboplatin/paclitaxel treatment group had the largest elastic modulus (~6 times greater than 
the control) and a substantial increase in ECM constituents, suggesting that it is the density of the ECM (as 
opposed to cellular density) that could have been responsible for the observed stiffness increase in the treated 
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tumours. Further investigations of the quantitative relationship between these factors would be of interest to 
cancer research.
Limitations. The evaluation of the response to treatment in the present study was based on a comparative 
statistical analysis of the ADC distributions obtained from different treatment groups. The key statistical tool 
used, Mann-Whitney test, enables the detection of subtle changes in the ADC distributions; however, this test 
relies on the number of imaging voxels in the tumour ROIs being sufficiently large. At the same time, decrease 
in tumour area and the number of the tumours (and the accompanying reduction of the tumour ROIs) are 
unavoidable consequences of a successful treatment. Therefore, samples in the control group, or in groups 
with less effective treatments, will tend to have a larger tumour ROI (and more tumour voxels available for 
statistical analysis) than samples in the more responsive treatment groups. This was very apparent in the 
combination carboplatin/paclitaxel treatment group: only two samples were available for imaging, and of these, 
only one contained a solid tumour region. Therefore, the accuracy of the foregoing Mann-Whitney statistical 
analysis is inherently negatively biased in the case of successful treatment groups compared to the control and 
less successful treatment groups, single-agent paclitaxel or carboplatin, for which three and five samples, respec-
tively, were available for testing. In future studies, the number of animals per group should be at least doubled in 
order to allow for a sufficient number of tumours (n ~ 5) in the more successful treatment regimens for DW-MRI 
measurements and ADC analysis.
Conclusions
We have demonstrated that the distribution of the ADC and the maximum ADC value are well-suited for evaluat-
ing the response to chemotherapy in ovarian tumour xenografts. Changes in the ADC distribution in response to 
therapy varied and were dependent on anti-cancer agent. Treatment containing paclitaxel as single-agent induced 
changes in the high-cellularity regions of the tumour xenografts. The tumour area and the ECM gene expres-
sion analyses indicated that the combination carboplatin/paclitaxel-based regimen was more effective than the 
single-agent treatments. However, there was no distinction between the mean ADC of these tumour xenografts 
and the single-agent paclitaxel, indicating that the response of the tumour xenografts was majorly attributed to 
paclitaxel. We hypothesise that the reduction in ADC in the combination treatment group is a result of increased 
biosynthesis of the ECM constituents and recommend imaging different time points during treatment for future 
investigations. Such a study would also provide insight into the time dependence of ECM production in the 
tumour xenografts, leading to a better understanding of the role of ECM synthesis as a survival or apoptosis 
mechanism induced in chemotherapy.
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